Cure My Disease

Don't miss your cure!

 Log in / Sign up

Race to delay diabetes: drug trial aims to postpone full disease onset

NCT ID NCT06791291

Recruiting now Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

Summary

This study is testing if a 14-day intravenous treatment called teplizumab can safely delay the progression to full-blown type 1 diabetes in Japanese children and adults aged 8 to 34. Participants are in an early stage of the disease, where they have signs of it but no major symptoms yet. The goal is to see if the treatment can help the body's own insulin production last longer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Investigational Site Number : 3920001

    RECRUITING

    Iruma, Saitama, 350-0495, Japan

  • Investigational Site Number : 3920004

    RECRUITING

    Osaka, 545-8586, Japan

  • Investigational Site Number : 3920006

    RECRUITING

    Sapporo, Hokkaido, 060-8543, Japan

  • Investigational Site Number : 3920007

    RECRUITING

    Yahaba, Iwate, 028-3695, Japan

  • Investigational Site Number : 3920010

    RECRUITING

    Chūō, Yamanashi, 409-3898, Japan

  • Investigational Site Number : 3920015

    RECRUITING

    Ichikawa, Chiba, 272-0827, Japan

  • Investigational Site Number : 3920016

    RECRUITING

    Kyoto, 606-8507, Japan

  • Investigational Site Number : 3920017

    RECRUITING

    Fukuoka, 812-0025, Japan

  • Investigational Site Number : 3920018

    RECRUITING

    Kobe, Hyōgo, 650-0017, Japan

  • Investigational Site Number : 3920019

    RECRUITING

    Yokohama, Kanagawa, 222-0036, Japan

  • Investigational Site Number : 3920020

    RECRUITING

    Tokyo, 101-8309, Japan

Conditions

Explore the condition pages connected to this study.

TYPE 1 DIABETES MELLITUS